Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple-negative breast cancer
Marcelo Ramos Tejo Salgado MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorDenise Viana Sobral MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorMario R. Martins MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorEduardo Forte M. T. Salgado MD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorAmanda Forte M. T. Salgado MD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorKamylla Ramos da Silva MSc
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorFernando Augusto Soares MD, PhD
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorCorresponding Author
Leuridan C. Torres PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Correspondence Leuridan C. Torres, PhD, Translational Research Laboratory, Instituto de Medicina Integral Professor Fernando Figueira (IMIP), P.O. Box 1393; Rua dos Coelhos, 300; Recife, PE 50070-550, Brazil.
Email: [email protected] and [email protected]
Search for more papers by this authorMarcelo Ramos Tejo Salgado MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorDenise Viana Sobral MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorMario R. Martins MD, PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorEduardo Forte M. T. Salgado MD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorAmanda Forte M. T. Salgado MD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorKamylla Ramos da Silva MSc
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Search for more papers by this authorFernando Augusto Soares MD, PhD
International Research Center, A.C. Camargo Cancer, CenterSão Paulo, Brazil
Search for more papers by this authorCorresponding Author
Leuridan C. Torres PhD
Department of Research, Translational Research Laboratory, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil
Sociedade Pernambucana de Combate ao Cancer, Hospital de Câncer de Pernambuco (HCP), Recife, Brazil
Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Correspondence Leuridan C. Torres, PhD, Translational Research Laboratory, Instituto de Medicina Integral Professor Fernando Figueira (IMIP), P.O. Box 1393; Rua dos Coelhos, 300; Recife, PE 50070-550, Brazil.
Email: [email protected] and [email protected]
Search for more papers by this authorAbstract
Background
Locally advanced triple-negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC).
Methods
This was a longitudinal study with follow-up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre-NAC) and after NAC (Post-NAC).
Results
Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p < 0.05). Patients with pathological complete response (pCR) had low FAS+ T cells, FAS+CD4+ T cells, and PD1+CD8+ T cells compared to the non-pCR (p < 0.05). Significant differences were observed in the levels of CD28+ T cells, FAS+ T and PD1+ T, CD4+ T, CD28+CD4+ T, FAS+CD4+ T, PD1+CD4+ T, CD8+ T, and PD1+CD8+ T cells between Pre-NAC and Post-NAC groups (p < 0.05).
Conclusion
Alterations in the circulating FAS+CD4+ T and PD1+CD8+ T cell levels Pre-NAC are associated with pCR, suggesting potential predictive biomarkers of NAC response in TNBC. The largest changes in the cellular immune response profile Post-NAC showed that chemotherapy treatment can modulate the immune response and that it is associated with prognosis in TNBC.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.
- 2Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378: 1812-1823.
- 3Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747.
- 4Smith TJ. Breast cancer surveillance guidelines. J Oncol Pract. 2013; 9(1): 65-67.
- 5Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.
- 6 Abstract in a meeting program: Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathological features and sites of recurrence according to breast cancer subtypes in the National Comprehensive Cancer Network (NCCN) [Abstract]. American Society of Clinical Oncology (ASCO) first annual meeting 2009 J Clin Oncol. 2009; 27(15_suppl): A543.
- 7Millikan RC, Newman B, Tse C-K, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109: 123-139.
- 8Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1157-1166.
- 9Simon S, Bines J, Barrios C, et al. Clinical characteristics and outcomes of treatment of Brazilian women with breast cancer treated at public and private institutions—the AMAZONE III project of Brazilian Breast Cancer Group (GBECAM). Cancer Res. 2009; 69(24 suppl): A3082.
- 10Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome ofBRCAMutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17: 1082-1089.
- 11Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26: 1275-1281.
- 12Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13: 2329-2334.
- 13Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; 137: 307-314.
- 14Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008; 26(5): 814-819.
- 15Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30: 1796-1804.
- 16Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384: 164-172.
- 17Spring LM, Fell G, Arfe A, et al. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: individual patient-level meta-analyses of over 27,000 patients. Cancer Res. 2018; 79:GS2-03.
10.1158/1538-7445.SABCS18-GS2-03 Google Scholar
- 18Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018; 29: 1497-4508.
- 19Debien V, De Caluwé A, Wang X, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023; 9(1): 7.
- 20Verma C, Eremin JM, Robins A, et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarized T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of Treg levels with pathological response to NAC. J Transl Med. 2013; 11: 16.
- 21Rathmell JC, Cooke MP, Ho WY, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4 T cells. Nature. 1995; 376: 181-184.
- 22Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA. 1997; 94: 13862-13867.
- 23Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 1998; 280: 243-248.
- 24Lenardo M, Chan FKM, Hornung F, et al. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999; 17: 221-253.
- 25Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science. 1993; 262: 905-907.
- 26Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229: 12-26.
- 27Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol. 2006; 176: 2808-2816.
- 28Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26: 677-704.
- 29Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 2002; 8: 793-800.
- 30Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 1999; 5: 1365-1369.
- 31Selenko-Gebauer N, Majdic O, Szekeres A, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol. 2003; 170: 3637-3644.
- 32Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8: 190-198.
- 33Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2: 261-268.
- 34Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013; 139: 667-676.
- 35Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6: 5449-5464.
- 36Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017; 67(2): 93-99. doi:10.3322/caac.21388
- 37Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017; 43: 604-611.
- 38Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med. 2017; 15: 55.
- 39Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379: 2108-2121.
- 40Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7− CD28− T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996; 97(9): 2027-2037.
- 41Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28− T cells in rheumatoid arthritis. Mol Med. 1996; 2(5): 608-618.
- 42Warrington KJ, Vallejo AN, Weyand CM, Goronzy J. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood. 2003; 101(9): 3543-3549.
- 43Gong J, Pan W, Yang C, Guo F, Sun Y. Expression of co-stimulators CD28/B7-1 in peripheral blood of patients with breast cancer. Breast Cancer Res Treat. 2012; 136(2): 621-622.
- 44Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999; 402: 255-262.
- 45Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008; 224: 166-182.
- 46Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161: 205-214.
- 47Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267-296.
- 48El-Sarha AI, Magour GM, Zaki SM, El-Sammak MY. Serum sFas and tumor tissue fasl negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma. Pathol Oncol Res. 2009; 15: 241-250.
- 49Malleter M, Tauzin S, Bessede A, et al. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 2013; 73: 6711-6721.
- 50Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236: 219-242.
- 51Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005; 25: 9543-9553.
- 52Koganemaru S, Inoshita N, Miura Y, et al. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Sci. 2017; 108: 853-858.
- 53Zhang M, Wang D, Sun Q, et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget. 2017; 8: 51630-51640.
- 54Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PDL1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 2017; 23: 5024-5033.
- 55Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999; 98: 47-58.
- 56Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2: 361-370.
- 57Disis ML. Immune regulation of cancer. J Clin Oncol. 2010; 28(29): 4531-4538.
- 58García-Martínez E, Gil GL, Benito AC, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014; 16: 488.
- 59Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with Tumor-Infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015; 3(4): 326-332.
- 60Radosevic-Robin N, Béguinot M, Penault-Llorca F. Évaluation de l'infiltrat immun dans le cancer du sein. Bull Cancer. 2017; 104(1): 52-68.
- 61Kim ST, Jeong H, Woo OH, et al. Tumor infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013; 36: 224-231.
- 62Savas P, Virassamy B, Ye C, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Med. 2018; 24: 986-993.
- 63Mahmoud SMA, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29: 1949-1955.
- 64Sasaki Y, Tsuda H. Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer. 2009; 16: 254-259.
- 65Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends in Cancer. 2015; 1: 66-75.
- 66Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016; 2: 1354-1360.
- 67Domschke C, Schneeweiss A, Stefanovic S, et al. Cellular immune responses and immune escape mechanisms in breast cancer: determinants of immunotherapy. Breast Care. 2016; 11: 102-107.
- 68He Q, Li G, Ji X, et al. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Tumor Biol. 2017; 39(5):101042831769757.
10.1177/1010428317697571 Google Scholar
- 69Asano Y, Kashiwagi S, Goto W, et al. Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med. 2018; 16: 87.
- 70Andre F, Berrada N, Desmedt C. Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 2010; 22(6): 547-551.
- 71Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28(1): 105-113.
- 72Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012; 132(3): 793-805.
- 73Mahmoud SMA, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012; 132: 545-553.
- 74Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013; 109: 2705-2713.
- 75Ladoire S, Mignot G, Dabakuyo S, et al. In situimmune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011; 224: 389-400.
- 76Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31: 860-867.
- 77Hornychová H, Melichar B, Tomšová M, Mergancová J, Urminská H, Ryška A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 2008; 26: 1024-1031.
- 78Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014; 20: 5995-6005.
- 79El Bairi K, Haynes HR, Blackley E, et al. International Immuno-Oncology biomarker working group. the tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021; 7(1): 150.
